FDA par­tial­ly halts Nurix Ther­a­peu­tics’ can­cer tri­al as it im­proves man­u­fac­tur­ing process

The FDA is paus­ing pa­tient en­roll­ment and screen­ing for Nurix Ther­a­peu­tics’ Phase I clin­i­cal tri­al for a po­ten­tial drug to treat B-cell ma­lig­nan­cies in can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER